| Written | 1997-12 | Jean-Loup Huret |
| Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France |
| Identity |
| Alias_names | myeloid/lymphoid or mixed-lineage leukemia |
| Alias_symbol (synonym) | AF-9 |
| AF9 | |
| YEATS3 | |
| Other alias | LTG9 |
| AF9 (ALL1 fused gene from chromosome 9) | |
| HGNC (Hugo) | MLLT3 |
| LocusID (NCBI) | 4300 |
| Atlas_Id | 5 |
| Location | 9p21.3 [Link to chromosome band 9p21] |
| Location_base_pair | Starts at 20341665 and ends at 20622543 bp from pter ( according to hg19-Feb_2009) [Mapping MLLT3.png] |
 | |
| AF9 (9p22) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics. | |
| Fusion genes (updated 2017) | Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands) |
| KMT2A (11q23.3) / MLLT3 (9p21.3) | KMT2B (19q13.12) / MLLT3 (9p21.3) | MLLT3 (9p21.3) / CISD3 (17q12) | |
| MLLT3 (9p21.3) / IZUMO3 (9p21.3) | MLLT3 (9p21.3) / KMT2A (11q23.3) | MLLT3 (9p21.3) / SLC28A3 (9q21.32) | |
| PAX5 (9p13.2) / MLLT3 (9p21.3) | SCFD1 (14q12) / MLLT3 (9p21.3) |
| DNA/RNA |
| Transcription | 5 kb mRNA; coding sequence: 1.7 kb |
| Protein |
| Description | 568 amino acids; 63 kDa; serine and proline rich in many places; possesses a nuclear targeting sequence |
| Localisation | nuclear |
| Function | transcription activator |
| Homology | with ENL (human) |
| Implicated in |
| Note | |
| Entity | t(9;11) (p22;q23)/AML -->KMT2A -MLLT3 |
| Disease | M5/M4 de novo and therapy related AML |
| Prognosis | the prognosis may not be as poor as in other 11q23 leukaemias in de novo cases; very poor prognosis in secondary AML cases |
| Cytogenetics | may be overlooked; often as a sole anomaly |
| Hybrid/Mutated Gene | variable breakpoints on both genes |
| Abnormal Protein | N-term -- AT hook and DNA methyltransferase from MLL fused to the 192 C-term amino acids from AF9 (as breakpoints are variable, this is only an exemple) |
| Bibliography |
| Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation. |
| Albain KS, Le Beau MM, Ullirsch R, Schumacher H |
| Genes, chromosomes & cancer. 1990 ; 2 (1) : 53-58. |
| PMID 2177642 |
| Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. |
| Bernard OA, Berger R |
| Genes, chromosomes & cancer. 1995 ; 13 (2) : 75-85. |
| PMID 7542910 |
| Identification of MLL and chimeric MLL gene products involved in 11q23 translocation and possible mechanisms of leukemogenesis by MLL truncation. |
| Joh T, Kagami Y, Yamamoto K, Segawa T, Takizawa J, Takahashi T, Ueda R, Seto M |
| Oncogene. 1996 ; 13 (9) : 1945-1953. |
| PMID 8934541 |
| 11q23 rearrangements in acute leukemia. |
| Rubnitz JE, Behm FG, Downing JR |
| Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1996 ; 10 (1) : 74-82. |
| PMID 8558942 |
| Chromosome abnormalities in leukaemia: the 11q23 paradigm. |
| Young BD, Saha V |
| Cancer surveys. 1996 ; 28 : 225-245. |
| PMID 8977038 |
| Citation |
| This paper should be referenced as such : |
| Huret, JL |
| AF9 (ALL1 fused gene from chromosome 9) |
| Atlas Genet Cytogenet Oncol Haematol. 1997;1(2):58-58. |
| Free journal version : [ pdf ] [ DOI ] |
| On line version : http://AtlasGeneticsOncology.org/Genes/AF9ID5.html |
| Other Leukemias implicated (Data extracted from papers in the Atlas) [ 9 ] |
| Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 3 ] |
|
t(9;9)(p21;p21) MLLT3/IZUMO3
t(9;9)(p21;q21) MLLT3/SLC28A3 t(9;17)(p21;q12) MLLT3/CISD3 |
| External links |
| REVIEW articles | automatic search in PubMed |
| Last year publications | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Fri Jun 22 16:59:35 CEST 2018 |
For comments and suggestions or contributions, please contact us